https://www.selleckchem.com/pr....oducts/Elesclomol.ht
creased to 1.1% after SOF use. Only 0.5% and 1.6% of the patients progressed to AKIN II and AKIN III elevation, respectively. CONCLUSION The direct-acting antivirals were safe and efficacious in CKD patients treated with SOF-containing regimens, with the observation of high SVR rates, good tolerability and few severe adverse events. The combination with ribavirin increased the risk of anemia and the administration of escalating doses seems to be useful in patients with GFR less then 60 mL/min. In patients with GFR less then 30 mL/min
Aimer
Commentaire
Partagez
